• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • HIV Drugs Companies

    ID: MRFR/HC/6984-HCR
    110 Pages
    Kinjoll Dey
    September 2025

    HIV drugs are designed to inhibit the replication of the virus, delay the progression of the disease, and enhance the immune system. Companies involved in the development, manufacturing, and distribution of drugs for the treatment of Human Immunodeficiency Virus (HIV) play a crucial role in managing and controlling HIV infections. 

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    HIV Drugs Market Research Report - Forecast till 2034 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the HIV Drugs Market

    Human Immunodeficiency Virus Drugs Key Companies

     

    Latest Human Immunodeficiency Virus Drugs Companies Update


    Gilead Sciences (US) Received approvals for their long-acting injectable HIV treatment Sunlenca® (lenacapavir) in combination with other antiretrovirals, offering convenient and effective therapy options.Partnered with research institutions on developing a long-acting injectable combination of lenacapavir with islatravir for potential quarterly dosing.


    Merck & Co. Completed Phase III trials for their investigational drug islatravir with potential advantages like once-daily dosing and fewer side effects, further diversifying their HIV treatment portfolio.Collaborated with advocacy groups to raise awareness about HIV testing and access to medications, particularly in marginalized communities.


    ViiV Healthcare (UK) Introduced their Cabenuva® (Cabotegravir, Rilpivirine LA) long-acting injection for HIV treatment, providing a bimonthly dosing option for eligible patients.Focused on expanding global access to their HIV medications through partnerships with public health organizations and development agencies.


    Janssen Pharmaceuticals (US) Received FDA approval for their new single-tablet regimen, Rukobia® (Fostemsavir, Tenofovir Alafenamide), simplifying treatment for individuals with multidrug-resistant HIV infections.Continued research on novel HIV prevention strategies, including long-acting injectable pre-exposure prophylaxis (PrEP) options.


    Joint United Nations Programme on HIV/AIDS (UNAIDS) Launched the Fast-Track Cities initiative to accelerate progress towards ending AIDS in 30 high-burden cities by 2030, focusing on early diagnosis, treatment access, and social interventions.Advocated for increased global funding for HIV research and development, particularly for affordable and accessible treatment options in resource-limited settings.


    List of Human Immunodeficiency Virus Drugs Key Companies in The Market



    • Boehringer Ingelheim International GmbH (Germany)

    • Cipla Inc. (India)

    • Merck & Co., Inc. (US)

    • AbbVie Inc. (US)

    • Bristol-Myers Squibb Company (US)

    • Teva Pharmaceutical Industries Ltd (Israel)

    • Gilead Sciences, Inc. (US)

    • Hoffmann-La Roche Ltd (Switzerland)

    • Pfizer Inc. (US)

    • Aurobindo Pharma (India)

    • Celltrion Healthcare Co., Ltd (South Korea)

    • ViiV Healthcare (UK)